Clinical Utility of the aMAP Score for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B

被引:2
作者
Chaiwiriyawong, Supakorn [1 ]
Assawasuwannakit, Suraphon [2 ]
Feuangwattana, Poorikorn [3 ]
Sripongpun, Pimsiri [3 ]
Chamroonkul, Naichaya [3 ]
Piratvisuth, Teerha [4 ]
Kaewdech, Apichat [3 ]
机构
[1] Prince Songkla Univ, Fac Med, Div Internal Med, Hat Yai 90110, Thailand
[2] Srinakharinwirot Univ, Panyananthaphikkhu Chonprathan Med Ctr, Dept Med, Nonthaburi 11120, Thailand
[3] Prince Songkla Univ, Fac Med, Div Internal Med, Gastroenterol & Hepatol Unit, Hat Yai 90110, Thailand
[4] Prince Songkla Univ, Songklanagarind Hosp, NKC Inst Gastroenterol & Hepatol, Hat Yai 90110, Thailand
关键词
HCC; aMAP score; chronic hepatitis B; surveillance; Thailand; RISK SCORE;
D O I
10.3390/diagnostics14131325
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to evaluate the efficacy of the aMAP score and compare it with other risk scores for predicting hepatocellular carcinoma (HCC) development in Thai patients with chronic hepatitis B (CHB). We retrospectively analyzed patients with CHB between 1 January 2008 and 31 December 2019. Data on demographics, clinical parameters, cirrhosis status, HCC imaging, and alpha fetoprotein surveillance were collected to calculate the aMAP score (0-100) based on age, sex, albumin-bilirubin level, and platelet count. Of the 1060 patients analyzed, 789 were eligible, of whom 51 developed HCC. The cumulative HCC incidences in the low-, moderate-, and high-risk groups at 3, 5, and 10 years were significantly different (log-rank, p < 0.0001). The area under the receiver operating characteristic curves (AUROCs) of the aMAP scores for predicting HCC at 3, 5, and 10 years were 0.748, 0.777, and 0.784, respectively. Among the risk scores, the CU-HCC score had the highest AUROCs (0.823) for predicting 5-year HCC development. The aMAP score is a valuable tool for predicting HCC risk in Thai patients with CHB and can enhance surveillance strategies. However, its performance is inferior to that of the CU-HCC score, suggesting the need for new predictive tools for HCC surveillance.
引用
收藏
页数:11
相关论文
共 25 条
[1]   A Recent Prevalence of Hepatitis B Virus (HBV) Genotypes and Subtypes in Asia: A Systematic Review and Meta-Analysis [J].
Bello, Kizito Eneye ;
Mat Jusoh, Tuan Nur Akmalina ;
Irekeola, Ahmad Adebayo ;
Abu, Norhidayah ;
Amin, Nur Amalin Zahirah Mohd ;
Mustaffa, Nazri ;
Shueb, Rafidah Hanim .
HEALTHCARE, 2023, 11 (07)
[2]   Hepatitis B Virus DNA Levels and Outcomes in Chronic Hepatitis B [J].
Chen, Chien-Jen ;
Yang, Hwai-I ;
Iloej, Uchenna H. .
HEPATOLOGY, 2009, 49 (05) :S72-S84
[3]   Epidemiology and treatment of hepatocellular carcinoma in Thailand [J].
Chonprasertsuk, Soonthorn ;
Vilaichone, Ratha-korn .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (04) :294-297
[4]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[5]   aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis [J].
Fan, Rong ;
Papatheodoridis, George ;
Sun, Jian ;
Innes, Hamish ;
Toyoda, Hidenori ;
Xie, Qing ;
Mo, Shuyuan ;
Sypsa, Vana ;
Guha, Indra Neil ;
Kumada, Takashi ;
Niu, Junqi ;
Dalekos, George ;
Yasuda, Satoshi ;
Barnes, Eleanor ;
Lian, Jianqi ;
Suri, Vithika ;
Idilman, Ramazan ;
Barclay, Stephen T. ;
Dou, Xiaoguang ;
Berg, Thomas ;
Hayes, Peter C. ;
Flaherty, John F. ;
Zhou, Yuanping ;
Zhang, Zhengang ;
Buti, Maria ;
Hutchinson, Sharon J. ;
Guo, Yabing ;
Calleja, Jose Luis ;
Lin, Lanjia ;
Zhao, Longfeng ;
Chen, Yongpeng ;
Janssen, Harry L. A. ;
Zhu, Chaonan ;
Shi, Lei ;
Tang, Xiaoping ;
Gaggar, Anuj ;
Wei, Lai ;
Jia, Jidong ;
Irving, William L. ;
Johnson, Philip J. ;
Lampertico, Pietro ;
Hou, Jinlin .
JOURNAL OF HEPATOLOGY, 2020, 73 (06) :1368-1378
[6]   AASLD guidelines for the treatment of hepatocellular carcinoma [J].
Heimbach, Julie K. ;
Kulik, Laura M. ;
Finn, Richard S. ;
Sirlin, Claude B. ;
Abecassis, Michael M. ;
Roberts, Lewis R. ;
Zhu, Andrew X. ;
Murad, M. Hassan ;
Marrero, Jorge A. .
HEPATOLOGY, 2018, 67 (01) :358-380
[7]   Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis [J].
Huang, Ze-Hong ;
Lu, Gui-Yang ;
Qiu, Ling-Xian ;
Zhong, Guo-Hua ;
Huang, Yue ;
Yao, Xing-Mei ;
Liu, Xiao-Hui ;
Huang, Shou-Jie ;
Wu, Ting ;
Yuan, Quan ;
Wang, Ying-Bin ;
Su, Ying-Ying ;
Zhang, Jun ;
Xia, Ning-Shao .
BMC CANCER, 2022, 22 (01)
[8]   Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade [J].
Johnson, Philip J. ;
Berhane, Sarah ;
Kagebayashi, Chiaki ;
Satomura, Shinji ;
Teng, Mabel ;
Reeves, Helen L. ;
O'Beirne, James ;
Fox, Richard ;
Skowronska, Anna ;
Palmer, Daniel ;
Yeo, Winnie ;
Mo, Frankie ;
Lai, Paul ;
Inarrairaegui, Mercedes ;
Chan, Stephen L. ;
Sangro, Bruno ;
Miksad, Rebecca ;
Tada, Toshifumi ;
Kumada, Takashi ;
Toyoda, Hidenori .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :550-U45
[9]   Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients [J].
Kaewdech, Apichat ;
Sripongpun, Pimsiri ;
Cheewasereechon, Natcha ;
Jandee, Sawangpong ;
Chamroonkul, Naichaya ;
Piratvisuth, Teerha .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (02) :E00310
[10]  
Kim JH, 2018, J HEPATOL, V69, P1066, DOI [10.1016/s0168-8278(18)31215-7, 10.1016/j.jhep.2018.07.018]